360 related articles for article (PubMed ID: 16785112)
1. Botulinum toxin therapy for cervical dystonia.
Jankovic J
Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
[TBL] [Abstract][Full Text] [Related]
2. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
4. Xeomin in the treatment of cervical dystonia.
Benecke R
Eur J Neurol; 2009 Dec; 16 Suppl 2():6-10. PubMed ID: 20002740
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of botulinum toxins for the treatment of cervical dystonia.
Brashear A
Expert Opin Drug Saf; 2005 Mar; 4(2):241-9. PubMed ID: 15794717
[TBL] [Abstract][Full Text] [Related]
6. A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
Med Lett Drugs Ther; 2010 Nov; 52(1351):90-1. PubMed ID: 21068703
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of focal dystonia with botulinum toxin A].
Sojer M; Wissel J; Müller J; Poewe W
Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
Dressler D; Bigalke H
J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
[TBL] [Abstract][Full Text] [Related]
12. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
[TBL] [Abstract][Full Text] [Related]
13. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
Marion MH; Humberstone M; Grunewald R; Wimalaratna S
Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
Moll M; Rosenthal D; Hefter H
Parkinsonism Relat Disord; 2018 Dec; 57():63-67. PubMed ID: 30150129
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
17. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
Dressler D; Hallett M
Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
[TBL] [Abstract][Full Text] [Related]
18. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
[TBL] [Abstract][Full Text] [Related]
19. Cervical dystonia: from pathophysiology to pharmacotherapy.
Patel S; Martino D
Behav Neurol; 2013; 26(4):275-82. PubMed ID: 22713419
[TBL] [Abstract][Full Text] [Related]
20. Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment.
Camargo CH; Cattai L; Teive HA
Toxins (Basel); 2015 Jun; 7(6):2321-35. PubMed ID: 26110508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
